Brief: Elicera Concludes Preclinical Proof-Of-Concept Studies For Elc-201
April 27 (Reuters) - Elicera Therapeutics AB ELIC.ST :
* ELICERA THERAPEUTICS SUCCESSFULLY CONCLUDES PRECLINICAL
PROOF-OF-CONCEPT STUDIES FOR ONCOLYTIC VIRUS ELC-201 CONFIRMING
THE PROPOSED MODE-OF-ACTION
* STUDY RESULTS CONFIRM ELC-201'S PROPOSED MODE-OF-ACTION
Source text for Eikon: ID:nWkr4PdyPd
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Nomination Committee Proposes Margareth Jorvid As Chair Of Elicera Board
Brief: Elicera Therapeutics Carries Out Rights Issue Of About SEK 73 Mln
Sweden's Elicera Therapeutics Q1 loss narrows, reports positive clinical progress
Brief: Elicera Therapeutics Q1 Operating Loss SEK 5.1 Mln
Brief: Elicera Therapeutics Gets Notice Of Allowance For Japanease Patent